Back to Stakeholders

Levitee Labs Inc. is a British Columbia company that was incorporated on January 23, 2019 and later became listed on the Canadian Securities Exchange under the symbol LVT. Public filings describe it as an integrative wellness company with activities aimed at alternative medicine and the broader psychedelic industry.

The company’s public disclosures frame its role around acquiring and building wellness assets complementary to the evolving psychedelic sector, including clinics, pharmacies, nutraceuticals, and other adjacent healthcare businesses. That makes Levitee Labs relevant as an operator and capital allocator around psychedelic-adjacent healthcare infrastructure rather than a traditional early-stage venture fund.

Clinical Care Delivery Snapshot

Specialty & Outpatient Clinics

Provider Model

Independent Specialty Clinic

Organization Status

Unknown

Psychedelic Services

Unknown

Service Coverage

Global

Service Profile

Care Settings

Specialty Outpatient Clinic

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Seeded from user-provided care-delivery.xlsx list. Contacts: Sakshi Dwivedi (Clinic Manager) Contact emails: hello@leviteelabs.com Contact phones: 1-800-465-8640

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Levitee Labs appears to be a public Canadian integrative wellness company with a psychedelic-adjacent mandate, not a conventional venture fund. Its strategy has been described in filings and announcements as building a portfolio of healthcare and wellness assets through acquisitions, with stated focus areas that include addiction services, mental healthcare, and assets complementary to the evolving psychedelic industry. Public records also show financing activity and acquisitions rather than a disclosed standalone venture portfolio.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Venture Capital Fund

Investment Website

Quick Facts

Founded
2019
HQ
Vancouver, British Columbia, Canada
Website
Visit